Abstract
Background Recent studies have leveraged quantitative traits from imaging to amplify the power of genome-wide association studies (GWAS) to gain further insights into the biology of diseases and traits. However, measurement imprecision is intrinsic to phenotyping and can impact downstream genetic analyses.
Methods Left ventricular ejection fraction (LVEF), an important but imprecise quantitative imaging measurement, was examined to assess the impact of precision of phenotype measurement on genetic studies. Multiple approaches to obtain LVEF, as well as simulated measurement noise, were evaluated with their impact on downstream genetic analyses.
Results Even within the same population, small changes in the measurement of LVEF drastically impacted downstream genetic analyses. Introducing measurement noise as little as 7.9% can eliminate all significant genetic associations in an GWAS with almost forty thousand individuals. An increase of 1% in mean absolute error (MAE) in LVEF had an equivalent impact on GWAS power as a decrease of 10% in the cohort sample size, suggesting optimizing phenotyping precision is a cost-effective way to improve power of genetic studies.
Conclusions Improving the precision of phenotyping is important for maximizing the yield of genome-wide association studies.
What Is New?
Measurement imprecision in cardiac imaging phenotypes can substantially impact downstream genetic association studies, explaining much of the difference in identified genetic variants between echocardiography and cardiac magnetic resonance imaging.
Using the example of left ventricular ejection fraction as an important but imprecise clinical measurement, the analysis suggests that the measurement variation within the range of clinician interpretation reduced genome-wide association studies’ power to detect genetic risk factors as much as decreasing the study population size by 20%.
What Are the Clinical Implications?
More precise measurements can result in a better understanding of the genetics of cardiac phenotypes and accelerate the development of precision medicine.
Rather than simply increasing population size, improving measurement precision allows for cost-effective discovery of genetic associations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the National Institutes of Health NIH K99 HL157421.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available human data from UK Biobank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-senior author Contact: shoa{at}stanford.edu and David.ouyang{at}cshs.org
Data Availability
This paper analyzes UK Biobank data, which is available after the approval of an application at https://www.ukbiobank.ac.uk.
